Trial Profile
An Open-Label Phase Ib/II Study of the Safety, Tolerability and Efficacy of G207, a Genetically Engineered Herpes Simplex Type-1 Virus, Administered Intracerebrally to Patients With Recurrent Malignant Glioma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Jun 2014
Price :
$35
*
At a glance
- Drugs G 207 (Primary)
- Indications Glioma
- Focus Adverse reactions; Therapeutic Use
- Sponsors MediGene Inc
- 06 Jun 2014 New trial record